

194 disclosure



信息披露

修订前

2024年度变更募集资金投资项目情况表									
变更后项目	对应的原项目	变更后拟投入募集资金总额		截至前次计划累计投入募集资金金额(1)		本年度实际投入募集资金金额(2)		当年累计投入募集资金总额(3)=(2)-(1)	
		年	产	截至前次计划累计投入募集资金金额(1)	本年度实际投入募集资金金额(2)	当年累计投入募集资金总额(3)=(2)-(1)			
年产500万支家用聚丙烯膜聚合物复合材料及配套基础设施建设	年产500万支家用聚丙烯膜聚合物复合材料及配套基础设施建设	33,	33,	6,	10,	31,19	202	6,	
合计	一	33,	33,	6,	10,	31,19	-		
404.05	0405	396.28	304.68						

This image is a collage of numerous documents and certificates from Shanghai Yida Pharmaceutical Co., Ltd. It includes various types of reports such as financial statements, audit reports, and legal opinions. The documents are mostly in Chinese and appear to be from different years, including 2023, 2022, and 2021. Some of the visible text includes "Shanghai Yida Pharmaceutical Co., Ltd.", "Annual Report", "Audit Report", and "Legal Opinion". The layout is dense and overlapping, suggesting a collection of important corporate records.

The image shows a scanned document of a company's annual report or notice. The title at the top reads '上海谊众药业股份有限公司关于高级管理人员2025年薪酬方案的公告'. Below the title, there is detailed text regarding the compensation scheme for senior management in 2025, including performance metrics and specific amounts. The document also includes sections for shareholders' rights, legal basis, and other administrative details.